The Eyevensys has a small but fully dedicated team of 7 people, who manage and coordinate a network of external professional designers, product development specialists, CROs, regulatory advisors, and industrial partners.
Mr. Raffy Kazandjian, President & CEO
Joined the company in March 2014 with over 25 years of experience in biotechnology and venture-capital industry. Former President of CDC-Innovation, a French venture-capital fund, from 1998 to 2002, he had 300 M€ under management, most of which he had raised. All along his career, Mr. Kazandjian supervised over 70 investments in technology start-ups, held numerous board positions, and assisted several biotech Companies, including companies such as Cellectis in their financing and growth strategies. Mr Kazandjian is a graduate from MIT(MS’85) and from the European Business School INSEAD (MBA’90).
Dr. Francine Behar-Cohen, Founder and Chief Scientific Officer of Eyevensys, MD, PhD.
Professor Francine Behar-Cohen is since 2013 the Chief Medical Officer of the Gonin Lausanne Ophthalmology Hospital in Switzerland. She was previously Professor of Ophthalmology at Paris Descartes University (France), Head of the Department of Ophthalmology of Hôtel-Dieu – University of Paris Descartes Hospital, and Director of of the “Physiopathology of Ocular Diseases lab at the Cordeliers INSERM Centre (UMRS 872). She has authored over 164 publications since 1999. Very entrepreneurially oriented, Professor Behar-Cohen founded Eyegate Pharma in 1997 (OPTIS Pharma), and Eyevensys in 2008.
Violaine Desort-Henin, DVM, Chief Clinical Director
Dr. Violaine Desort-Hénin combines several competences, from vet medicine and surgery to toxicology and clinical trial management, particularly in the area of ophthalmology. Various professional experiences have enabled her to acquire a translational medical expertise and a deep understanding of the complex physiopathology underlying ocular diseases. She was previously Head of Preclinical and Clinical Development in a listed biotech company for over 5 years. During her previous tenure, she participated in all phases of development up to clinical Phase III and participated in the design of strategic international programs.